• 2009 Molecular profiling to identify molecular mechanism in esophageal cancer with familial clustering

• 2010 Gene Expression: Protein Interaction Systems Network Modeling Identifies Transformation-Associated Molecules and Pathways in Ovarian Cancer



• 2010 p300 MEDIATED ACETYLATION OF HISTONE H3 LYSINE 56 FUNCTIONS IN DNA DAMAGE RESPONSE IN MAMMALS



• 2010 Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma



• 2010 Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma



• 2009 Analysis of chromosomal aberration (1, 3, and 8) and association of microRNAs in uveal melanoma



• 2009 Genome-wide changes accompanying the knockdown of Ep-CAM in retinoblastoma



• 2009 Multiple Biochemical and Morphological Factors Underlie the Production of Methylketones in Tomato Trichomes.



• 2009 Methylketone Biosynthesis in Tomato F2 Segregant Populations



• 2009 Heat shock factor gene family in rice: Genomic organization and transcript expression profiling in response to high temperature, low temperature and oxidative stresses



• 2009 Transcriptional Regulation and the Role of Galactose Metabolism in the Virulence of Candida albicans



• 2008 Evaluation of the pharmacodynamics effects of MGCD0103 from preclinical models to human



• 2008 The LysR-type transcriptional regulator Hrg counteracts phagocyte oxidative burst



• 2007 Gene expression profile of esophageal cancer in North East India by cDNA microarray analysis



• 2007 p53 Target Gene SMAR1 Is Dysregulated in Breast Cancer



• 2007 SMAR1 Derived P44 Peptide Retains Its Tumor Suppressor Function



• 2007 Gene expression profile of esophageal cancer in North East India



• 2007 Specific Inhibition of p300-HAT Alters Global Gene Expression



• 2006 Microarrays: Table of suppliers



• 2006 Transcriptional Co activator PC4, A Chromatin-associated Protein



• 2004 Polyisoprenylated Benzophenone, Garcinol, a Natural Histone



• 2004 Bioinformatics from genes to pathways



• 2002 Whole Genome Expression Profiles of Yeast RNA Polymerase II Core Subunit, Rpb4

• 2008, AACR Annual Meeting, MGCD0103, an oral HDAC inhibitor, significantly enhances the anti-tumor efficacy of taxanes via the unique modulation of angiogenesis gene expressions. Fujita, H. et al.,April 2008. (Oral presentation)


• 2008, AACR Annual Meeting, Induction of an anti-angiogenesis factor TSP-1 by a novel HDAC inhibitor, MGCD0103 in human cancer cells in vitro and in vivo, Bonfils, C. et al., April, 2008.


• 2007, AACR Annual Meeting, Induction of Interleukin-6 expression by the HDAC inhibitor, MGCD0103, in leukemia patients in vivo correlates with clinical efficacy, Maroun, C. et al., April 2007.


• 2007, AACR Annual Meeting, Induction of MT3 transcription as a pharmacodynamic biomarker for histone deacetylase inhibitor MGCD0103 in vitro and in vivo, Liu, J. et al., April 2007.

• Assay for efficacy of histone deacetylase inhibitors (microarrays done by genotypic and analysis by Genotypic's Biointerpreter) - United States Patent Application 20070292351


• Combination Therapy (microarrays done by genotypic and analysis by Genotypic's Biointerpreter) - United States Patent Application 20090124631

BANGALORE, INDIA, September 7, 2007 -- Genotypic Technology (P) Ltd. today announced that it has achieved Agilent Certified Microarray Service Provider status. Genotypic is the first Indian Company to be provided the Agilent Certified Service Provider status and the first in the world to be certified for all three Agilent solutions in Gene Expression, aCGH and location analysis.

"Over the last two years, we hope our customers benefited from Genotypic's microarray services as much as we did. We congratulate Genotypic on expanding their portfolio to all microarray applications and providing quality microarray services to a wide spectrum of customers worldwide. Genotypic is Agilent's reliable partner and we are very satisfied with their technical strength spanning from experiment design to data analysis" said Dr. Chris Tan Director for Asia Pacific, Genomics, Agilent Technologies.

Commenting on the announcement, Dr. Raja Mugasimangalam, President and CEO, Genotypic Technology said "It is our endeavour to consistently provide high quality genomics and bioinformatics solutions through continuous innovation. Our relationship with Agilent has been rewarding and one based on mutual trust. Our strength is in customizing solutions in the genomics space for our customers and our partnership with Agilent provides us with the right platform to do so. We feel honoured to be the first company in the world to be certified simultaneously for all three microarray applications."

Dr. Arindam Bhattacharjee, Senior Scientist, Genomics, Agilent Technologies highlighted "As Agilent continues to train and certify Service Providers to provide top quality microarray services to our customers worldwide, we are very satisfied with Genotypic's overall quality of service and their solid background in biology and informatics . This puts them in a unique position to assist our customers make microarray designs which addresses their biological questions. Genotypic also extends the usability of eArray (Agilent web-based design tool) by making it easier for customers to quickly design custom arrays. For most instances there is no service fee, making it very attractive to our customers."

About Genotypic Technology:
Genotypic Technology (www.genotypic.co.in) is a privately held Genomics R & D company specialising in microarray technology developing customised genomics and bioinformatics solutions for a wide-range of applications. Established in the year 2000, it is the first major Indian company catering to Academic institutions, Pharma and Biotech companies worldwide in the microarray space. Genotypic has successfully completed Gene Expression, aCGH, Location analysis (ChIP on Chip, Methylation and chromatin modulations projects using Agilent platform. The certification of Genotypic's microarray services by Agilent ensures customers will receive results with the superior sensitivity, quality and reliability of Agilent Microarray Platform.

Customers worldwide trust Genotypic to deliver on their microarray needs from simple array processing to more challenging projects that involve brain storming of array design, project planning and analysis. Genotypic has carried out wide range of microarray projects like Bacterial Biosensor microarrays, Gene expression profiling of sequenced and un-sequenced organisms, Epigenetic modifications, Cancer biomarker discovery, toxicity profiling, drug optimization, pathway profiling of drug action, responders and non-responders of drug treatment from clinical trials and drug repurposing.

Genotypic is an R&D and custom array design partner of Agilent's location analysis unit and provides eArray based custom microarray designs for all applications of microarray.

Genotypic also provides indigenous informatics solutions like Biointerpreter and MedRuner that enable biological interpretation of microarray data in a short period of time. Genotypic's microarray services include project consultancy and post array analysis using GeneSpring, Biointerpreter and MedRuner.